These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 34443652)
1. Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone. Timoshnikov VA; Kichigina LA; Selyutina OY; Polyakov NE; Kontoghiorghes GJ Molecules; 2021 Aug; 26(16):. PubMed ID: 34443652 [TBL] [Abstract][Full Text] [Related]
2. Redox Interactions of Vitamin C and Iron: Inhibition of the Pro-Oxidant Activity by Deferiprone. Timoshnikov VA; Kobzeva TV; Polyakov NE; Kontoghiorghes GJ Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486511 [TBL] [Abstract][Full Text] [Related]
3. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity. Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513 [TBL] [Abstract][Full Text] [Related]
5. The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency. Kontoghiorghes GJ Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731873 [TBL] [Abstract][Full Text] [Related]
6. Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine. Hašková P; Applová L; Jansová H; Homola P; Franz KJ; Vávrová K; Roh J; Šimůnek T Sci Rep; 2022 Jun; 12(1):9765. PubMed ID: 35697900 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. DivakarJose RR; Delhikumar CG; Ram Kumar G Indian J Pediatr; 2021 Apr; 88(4):330-335. PubMed ID: 32661609 [TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. Gomber S; Jain P; Sharma S; Narang M Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438 [TBL] [Abstract][Full Text] [Related]
10. Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine. Timoshnikov VA; Selyutina OY; Polyakov NE; Didichenko V; Kontoghiorghes GJ Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163169 [TBL] [Abstract][Full Text] [Related]
11. An ellagic acid isolated from Clerodendrum viscosum leaves ameliorates iron-overload induced hepatotoxicity in Swiss albino mice through inhibition of oxidative stress and the apoptotic pathway. Shendge AK; Basu T; Panja S; Chaudhuri D; Mandal N Biomed Pharmacother; 2018 Oct; 106():454-465. PubMed ID: 29990833 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987 [TBL] [Abstract][Full Text] [Related]
13. Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats. Rahdar A; Hajinezhad MR; Sargazi S; Bilal M; Barani M; Karimi P; Kyzas GZ Life Sci; 2021 Apr; 270():119146. PubMed ID: 33545199 [TBL] [Abstract][Full Text] [Related]
14. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Kontoghiorghes GJ; Efstathiou A; Kleanthous M; Michaelides Y; Kolnagou A Hemoglobin; 2009; 33(5):386-97. PubMed ID: 19814684 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of Fe(2+)- and Fe(3+)- induced hydroxyl radical production by the iron-chelating drug deferiprone. Timoshnikov VA; Kobzeva TV; Polyakov NE; Kontoghiorghes GJ Free Radic Biol Med; 2015 Jan; 78():118-22. PubMed ID: 25451643 [TBL] [Abstract][Full Text] [Related]
16. Metals, toxicity and oxidative stress. Valko M; Morris H; Cronin MT Curr Med Chem; 2005; 12(10):1161-208. PubMed ID: 15892631 [TBL] [Abstract][Full Text] [Related]
17. Destructive effect of iron overload in brain tissue of albino rats: Ameliorative role of silver immobilized organo-modified casein nanocomposite as co-treating agent with Deferasirox. Adel RM; Lotfy RA; Darwish AS; Amer AS J Trace Elem Med Biol; 2021 Sep; 67():126794. PubMed ID: 34052583 [TBL] [Abstract][Full Text] [Related]
18. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats. Emara AM; El Kelany RS; Moustafa KA Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166 [TBL] [Abstract][Full Text] [Related]
19. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Wood JC; Otto-Duessel M; Gonzalez I; Aguilar MI; Shimada H; Nick H; Nelson M; Moats R Transl Res; 2006 Nov; 148(5):272-80. PubMed ID: 17145573 [TBL] [Abstract][Full Text] [Related]
20. Iron toxicity and antioxidant nutrients. Fraga CG; Oteiza PI Toxicology; 2002 Oct; 180(1):23-32. PubMed ID: 12324197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]